Literature DB >> 21679264

Examining naltrexone and alcohol effects in a minority population: results from an initial human laboratory study.

Jennifer G Plebani1, David W Oslin, Kevin G Lynch.   

Abstract

Prior clinical findings have indicated a potential lack of naltrexone efficacy among African Americans with alcohol dependence. However, no definitive conclusions have been drawn due to the relatively small numbers of African Americans in most alcohol treatment trials. The purpose of this study was to examine alcohol and naltrexone effects on healthy African-American individuals in a laboratory environment. Nonalcohol-dependent social drinking adults of African descent (n = 43) were recruited for participation. After consenting and completing the baseline assessment, they participated in four separate alcohol challenge sessions each separated by at least 10 days. During each of the sessions, subjects were administered alcohol or sham drinks, after pretreatment with either naltrexone (50 mg/day) or placebo in a double-blind fashion. The order of the four sessions was randomly assigned. During each session, breath alcohol levels and subjective responses were measured. Results indicate an alcohol effect among these subjects for subjective responses, but no naltrexone effect. Similar to the apparent lack of clinical efficacy findings, naltrexone does not appear to impact alcohol effects in African-American social drinkers. Future studies should investigate African-American populations with heavy drinking as well as alcohol-dependent subjects in order to strengthen the parallels to clinical findings. © American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21679264      PMCID: PMC3124087          DOI: 10.1111/j.1521-0391.2011.00138.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  29 in total

Review 1.  Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire.

Authors:  K O Fagerstrom; N G Schneider
Journal:  J Behav Med       Date:  1989-04

2.  Effect of naltrexone on alcohol "high" in alcoholics.

Authors:  J R Volpicelli; N T Watson; A C King; C E Sherman; C P O'Brien
Journal:  Am J Psychiatry       Date:  1995-04       Impact factor: 18.112

Review 3.  Neuropeptides and alcohol addiction in monkeys.

Authors:  J M van Ree; M Kornet; C Goosen
Journal:  EXS       Date:  1994

4.  Psychometric properties and validity of the obsessive-compulsive drinking scale.

Authors:  M J Bohn; B A Barton; K E Barron
Journal:  Alcohol Clin Exp Res       Date:  1996-08       Impact factor: 3.455

5.  Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence.

Authors:  A C King; J R Volpicelli; A Frazer; C P O'Brien
Journal:  Psychopharmacology (Berl)       Date:  1997-01       Impact factor: 4.530

6.  Naltrexone-induced alterations in human ethanol intoxication.

Authors:  R M Swift; W Whelihan; O Kuznetsov; G Buongiorno; H Hsuing
Journal:  Am J Psychiatry       Date:  1994-10       Impact factor: 18.112

7.  Development and validation of the Biphasic Alcohol Effects Scale.

Authors:  C S Martin; M Earleywine; R E Musty; M W Perrine; R M Swift
Journal:  Alcohol Clin Exp Res       Date:  1993-02       Impact factor: 3.455

8.  Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference.

Authors:  J C Froehlich; J Harts; L Lumeng; T K Li
Journal:  Pharmacol Biochem Behav       Date:  1990-02       Impact factor: 3.533

Review 9.  Opiates and alcohol self-administration in animals.

Authors:  R R Ulm; J R Volpicelli; L A Volpicelli
Journal:  J Clin Psychiatry       Date:  1995       Impact factor: 4.384

10.  Naltrexone and coping skills therapy for alcohol dependence. A controlled study.

Authors:  S S O'Malley; A J Jaffe; G Chang; R S Schottenfeld; R E Meyer; B Rounsaville
Journal:  Arch Gen Psychiatry       Date:  1992-11
View more
  9 in total

Review 1.  Human laboratory paradigms in alcohol research.

Authors:  Jennifer G Plebani; Lara A Ray; Meghan E Morean; William R Corbin; James MacKillop; Michael Amlung; Andrea C King
Journal:  Alcohol Clin Exp Res       Date:  2012-02-06       Impact factor: 3.455

Review 2.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

Review 3.  Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic review.

Authors:  Martyna Sawicka; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2017-05-24

Review 4.  Less drinking, yet more problems: understanding African American drinking and related problems.

Authors:  Tamika C B Zapolski; Sarah L Pedersen; Denis M McCarthy; Gregory T Smith
Journal:  Psychol Bull       Date:  2013-03-11       Impact factor: 17.737

5.  Differences in subjective response to alcohol by gender, family history, heavy episodic drinking, and cigarette use: refining and broadening the scope of measurement.

Authors:  Meghan E Morean; William R Corbin; Teresa A Treat
Journal:  J Stud Alcohol Drugs       Date:  2015-03       Impact factor: 2.582

Review 6.  Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity.

Authors:  Anita Cservenka; Megan M Yardley; Lara A Ray
Journal:  Am J Addict       Date:  2016-11-04

7.  Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta-analysis.

Authors:  Lara A Ray; ReJoyce Green; Daniel J O Roche; Molly Magill; Spencer Bujarski
Journal:  Addict Biol       Date:  2019-05-30       Impact factor: 4.280

Review 8.  Advances in Substance Abuse Prevention and Treatment Interventions Among Racial, Ethnic, and Sexual Minority Populations.

Authors:  Arthur W Bloom
Journal:  Alcohol Res       Date:  2016

9.  Individual and county-level variation in outcomes following non-fatal opioid-involved overdose.

Authors:  Evan Marie Lowder; Joseph Amlung; Bradley R Ray
Journal:  J Epidemiol Community Health       Date:  2020-01-09       Impact factor: 3.710

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.